Sudeep Pharma Completes Q2FY26 Results Publication in Newspapers
Sudeep Pharma Limited completed regulatory compliance by publishing its Q2FY26 financial results extract in newspapers on December 20, 2025. The company reported consolidated revenue of ₹16,266.62 crores and net profit of ₹4,677.82 crores, with detailed results available on stock exchanges and company website.
*this image is generated using AI for illustrative purposes only.
Sudeep Pharma Limited has completed the publication of its Q2FY26 financial results extract in newspapers, fulfilling regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company published the results extract in Business Standard (English) and Vadodara Samachar (regional language) newspapers on December 20, 2025.
Regulatory Compliance
The company submitted the newspaper publication copies to both National Stock Exchange of India Limited and BSE Limited under Regulation 30 and 47 of SEBI (LODR) Regulations. Company Secretary Dimple Mehta confirmed that the financial results information is also available on the company's website at https://www.sudeeppharma.com/ .
| Compliance Parameter | Details |
|---|---|
| Publication Date | December 20, 2025 |
| English Newspaper | Business Standard |
| Regional Newspaper | Vadodara Samachar |
| Location | Vadodara, Gujarat |
| Regulation | SEBI (LODR) 30 & 47 |
Q2FY26 Financial Highlights
The published extract shows the company's consolidated financial performance for the quarter ended September 30, 2025:
| Financial Metric | Q2FY26 | Q2FY25 | Change (%) |
|---|---|---|---|
| Total Income from Operations | ₹16,266.62 cr | ₹14,879.91 cr | +9.32% |
| Net Profit After Tax | ₹4,677.82 cr | ₹4,874.83 cr | -4.04% |
| Profit Before Tax | ₹5,953.37 cr | ₹6,171.61 cr | -3.54% |
| Basic EPS | ₹4.20 | ₹4.49 | -6.46% |
Standalone Performance
On a standalone basis, the company reported total income from operations of ₹8,788.16 crores for Q2FY26 compared to ₹10,629.58 crores in the corresponding quarter of the previous year. Standalone profit after tax stood at ₹2,974.14 crores versus ₹2,945.04 crores in Q2FY25.
| Standalone Metrics | Q2FY26 | Q2FY25 | Change (%) |
|---|---|---|---|
| Total Income | ₹8,788.16 cr | ₹10,629.58 cr | -17.32% |
| Profit After Tax | ₹2,974.14 cr | ₹2,945.04 cr | +0.99% |
| Total Comprehensive Income | ₹2,980.04 cr | ₹2,932.84 cr | +1.61% |
Board Approval and Corporate Information
The unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors in meetings held on December 18 and 19, 2025, respectively. The company operates from its registered office at GIDC Nandesari, Baroda, Gujarat, with corporate office at Gotri-Sevasi Road, Vadodara.
The complete financial results are available on stock exchange websites (BSE scrip code: 544619, NSE symbol: SUDEEPHRM) and the company's official website. A QR code has been provided in the published extract for easy access to the detailed financial statements.
Historical Stock Returns for Sudeep Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.36% | -5.67% | -14.30% | -26.55% | -26.55% | -26.55% |
17
